Christine A. Ciunci, Rodolfo F. Perini, Anjali N. Avadhani, Hyunseon C. Kang, Weijing Sun, Maryann Redlinger, Kathleen Harlacker, Keith T. Flaherty, Bruce J. Giantonio, Mark A. Rosen, Chaitanya R. Divgi, Hee Kwon Song, Sarah Englander, Andrea Troxel, Mitchell Schnall and Peter J. O'Dwyer Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer Cancer 120
Article first published online: 24 SEP 2013 | DOI: 10.1002/cncr.28294
Everolimus and cetuximab can be safely administered in combination at standard doses, and are associated with prolonged disease control. Imaging studies reveal that the metabolic inhibition by everolimus alone and in combination with cetuximab predominates over changes in tumor perfusion in the patient population with advanced cancer.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.